BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Vaccines

Sanofi and AstraZeneca’s Beyfortus Gains Malaysia Approval to Protect All Infants from RSV

Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying...

November 25, 2025 | News

Everest Medicines Begins Global Phase I Trial of EVM14 as First Patient Receives Dose in the United States

The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated ...

November 24, 2025 | News

Apriori Bio and A STAR IDL Launch Strategic Partnership to Co Develop Next Generation saRNA Vaccines for Seasonal and Pandemic Influenza

Apriori Bio, a Flagship Pioneering company focused on developing prospective, variant-resilient vaccines, and the Agency for Science, Technology and Resear...

November 19, 2025 | News

Primrose Bio Launches Prima RNApols™ ExTend Cap AU to Enhance Self-Amplifying mRNA Vaccine Manufacturing

Primrose Bio, Inc. ("Primrose"), a company with proprietary therapeutic manufacturing technologies, announced the launch of Prima RNApols™ ...

November 11, 2025 | News

Akeso Initiates First-in-Human Trial of Personalised mRNA Vaccine AK154 for Pancreatic Cancer

Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vacc...

November 11, 2025 | News

High-Throughput Vaccine Production: The Future of Scalable, Rapid Immunisation

Vaccines remain the cornerstone of infectious disease control, but traditional development pathways are slow and resource‐intensive. Modern chall...

November 10, 2025 | Analysis

Takeda’s QDENGA Trial Confirms Sustained Protection and Favourable Safety Over Seven Years

Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule QDENGA is the Longest-Studied Dengue Vaccine and the ...

November 06, 2025 | News

Naobios and Tokyo Metropolitan Institute of Medical Science Partner to Develop Next-Generation Mpox Vaccine

Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, and the Tokyo Metropolitan Institute of Me...

October 27, 2025 | News

Singapore Approves Pfizer-BioNTech’s LP.8.1-Adapted COVID-19 Vaccine for Individuals Aged Six Months and Older

The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinic...

October 27, 2025 | News

Indonesia’s Bio Farma Strengthens Global Leadership in Vaccine Self-Reliance Through DCVMN Collaboration

Through PT Bio Farma (Persero), Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), wor...

October 22, 2025 | News

SK Bioscience Files Clinical Trial Application in Australia for GBP511 Universal Coronavirus Vaccine

Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses Phase 1/2 study to enroll ~500 healthy adults, with topline results e...

October 16, 2025 | News

Clover Biopharmaceuticals Reports Promising Phase I Results for RSV+hMPV±PIV3 Combination Vaccines

Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously...

October 15, 2025 | News

Everest Medicines Secures Dual IND Approvals for EVM14, Its First Internally Developed Therapeutic mRNA Cancer Vaccine

EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medic...

October 14, 2025 | News

GC Biopharma Secures Global CMO Rights for Curevo’s Recombinant Shingles Vaccine

GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced that it has signed an agreement with Curevo Vaccine to secure contract manufa...

October 14, 2025 | News

Stay Connected